Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Standard lipoprotein measurements may not adequately reflect the increased atherogenic risk found in patients with abnormalities in lipoprotein particle size and subfraction distribution such as disproportionate amounts of small, dense low‐density lipoprotein particles, small high‐density lipoprotein particles, or large very‐low‐density lipoprotein particles. Measurement or anticipation of patients most susceptible to lipoprotein subfraction abnormalities may influence therapeutic choices for the optimal management of dyslipidemia. Previously, the ADvicor Vs. Other Cholesterol‐modulating Agents Trial Evaluation demonstrated that niacin extended release/lovastatin provided greater global improvement in lipid parameters such as low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, lipoprotein (a), apolipoprotein B, and apolipoprotein A‐I blood levels compared with atorvastatin and simvastatin monotherapies. In this report, niacin extended release/lovastatin was also more effective than atorvastatin and simvastatin monotherapies in reducing small, dense low‐density lipoprotein particles and improving low‐density lipoprotein phenotype pattern at relative starting doses, and was more effective in increasing the proportion of high‐density lipoprotein in the potentially cardioprotective 2b subclass at all doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Gardner, C. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110029028 · Cited by 843
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Cited by
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 748
Safety considerations with niacin therapy
Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.018 · Cited by 269
Self-citation
Metadata
- Authors
- Bays, H. E., McGovern, M. E., & Kopin, L.
- Venue
- Preventive Cardiology
- Publisher
- Wiley
- Published
- 2003-10
- Volume
- 6
- Issue
- 4
- Pages
- 179-188
- ISSN
- 1520-037X (ISSN-L)
- 1751-7141
- OpenAlex
- W1971488182
- Cited by
- 65
- References
- 7
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin. https://app.cochat.ai/papers/10.1111/j.1520-037x.2003.03142.x
- The paper
- Bays, H. E., McGovern, M. E., & Kopin, L. (2003). Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin. Preventive Cardiology. https://doi.org/10.1111/j.1520-037x.2003.03142.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.